An ustekinumab biosimilar to Stelara launched in France, completing its rollout across 5 major European markets and paving ...

Will the Stelara biosimilars be a reprise of the Humira biosimilars in 2023 and be slow to catch on? Biosimilar watchers circled 2023 as a red-letter year because that was the year that the Humira ...

While speaking at the conference, J&J’s CEO, Joaquin Duato, indicated the company’s willingness to protect Stelara, its branded anti-interleukin (IL)-12/23 biologic, against sales erosion from ...

SAN FRANCISCO — When Eli Lilly last year started offering lower-priced vials of its blockbuster obesity drug Zepbound, which were previously sold in injectable pens, it framed the move as a way ...

Vigorous protection of Stelara’s position aligns with a strategy to grow in the immunology space. Credit: josefkubes via Shutterstock. During its presentation at the JP Morgan Healthcare Conference ...

The biosimilar, referencing Johnson & Johnson’s (NYSE: JNJ) Stelara, targets inflammatory conditions such as Crohn’s disease, ulcerative colitis, plaque psoriasis, and psoriatic arthritis. The ...

Stelara (ustekinumab) is a prescription drug that treats autoimmune conditions such as plaque psoriasis. You typically inject it subcutaneously (under your skin) or receive it intravenously ...

Stelara (ustekinumab) is a brand-name injectable drug prescribed for certain autoimmune conditions. Stelara has interactions with some other drugs and certain vaccines. Examples include Orencia ...

In treatment period 2, participants who received Stelara were re-randomized 1:1 to either continue ... and a 130mg/26mL single-dose vial for intravenous infusion. According to Celltrion, Steqeyma is ...